Submitted Successfully!
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Ver. Summary Created by Modification Content Size Created at Operation
1 + 1770 word(s) 1770 2021-09-24 06:14:21 |
2 format correct -1 word(s) 1769 2021-09-26 03:28:19 |

Video Upload Options

Do you have a full video?


Are you sure to Delete?
If you have any further questions, please contact Encyclopedia Editorial Office.
Gurnari, C. Large Granular Lymphocytic Leukemia. Encyclopedia. Available online: (accessed on 11 December 2023).
Gurnari C. Large Granular Lymphocytic Leukemia. Encyclopedia. Available at: Accessed December 11, 2023.
Gurnari, Carmelo. "Large Granular Lymphocytic Leukemia" Encyclopedia, (accessed December 11, 2023).
Gurnari, C.(2021, September 24). Large Granular Lymphocytic Leukemia. In Encyclopedia.
Gurnari, Carmelo. "Large Granular Lymphocytic Leukemia." Encyclopedia. Web. 24 September, 2021.
Large Granular Lymphocytic Leukemia

Large Granular Lymphocytic Leukemia (LGLL) represents about 2–5% of chronic lymphoproliferative disorders and predominantly affects the elderly (median age at diagnosis 66 years). Although the reported incidence is around 0.2 cases/1,000,000, the true prevalence may be much higher due to a large proportion of indolent, undiagnosed cases and, often, an inability to distinguish it from reactive cytotoxic T-cells (CTL) lymphoproliferation. The majority of LGLL cases are of the T subtype (i.e., derived from CTL), whereas only <10% are of natural killer (NK) cells origin.

large granular lymphocytic leukemia refractory disease immunogenomics

1. Introduction to Large Granular Lymphocytic Leukemia

Large Granular Lymphocytic Leukemia (LGLL) represents about 2–5% of chronic lymphoproliferative disorders and predominantly affects the elderly (median age at diagnosis 66 years) [1]. Although the reported incidence is around 0.2 cases/1,000,000, the true prevalence may be much higher due to a large proportion of indolent, undiagnosed cases and, often, an inability to distinguish it from reactive cytotoxic T-cells (CTL) lymphoproliferation. The majority of LGLL cases are of the T subtype (i.e., derived from CTL), whereas only <10% are of natural killer (NK) cells origin [2].

The diagnosis of LGLL is based on evidence of chronic clonal T- or NK-cell proliferation via cytology, immunophenotypic analysis, and TCR repertoires assessment. In cytology, circulating LGLL cells should be ≥0.5 × 10 9/L in the peripheral blood smear [3]. Cell phenotype by flow cytometry helps in identifying T-cells and NK-cells with an aberrant phenotype. In particular, T-LGLL shows CD3 + , CD8 + , and CD57 + expression whereas NK-LGLL expresses CD8 + , CD16 + , and CD56 + [2]. The evidence of T-LGLL clonal expansion may be assessed by using TCR γ -polymerase chain reaction analysis and Vβ gene rearrangement testing, which help to distinguish between reactive and leukemic LGLL cells. In rare situations, a bone marrow biopsy with immunohistochemistry studies may be helpful, especially when LGLL counts are too low or in the case of the NK-subtype because, in this case, it is not possible to study TCR-repertoires’ clonality [3][4].

Unlike other lymphomas, LGLL expansion is usually self-limited, persistent, and not associated with lymphadenopathy or “B symptoms”, although splenomegaly is present in about 24–50% of cases [5]. Cytopenias, a major presentation of LGLL, may result from direct cell-mediated targeting of myeloid precursors (neutropenia) or erythroid precursors (reticulocytopenic anemia), or indirectly through cytokine-mediated destruction of hematopoietic stem cells, representing an indication for treatment [6]. In addition to cytopenia(s), LGLL is frequently associated with autoimmune disorders or other accompanying conditions ( Figure 1 ) [7]. The pathogenetic link to these frequently co-occurring conditions remains speculative.

Figure 1. Diseases commonly associated with LGLL and schematic representation of underlying pathogenesis. MGUS: Monoclonal gammopathy of undetermined significance; PRCA: pure red cell aplasia; AIHA: autoimmune hemolytic anemia; MDS: Myelodysplastic syndrome; HSC: hematopoietic stem cell. AICD: activation-induced cell death; STAT: Signal Transducer and Activator of Transcription 3; TCR: T-cell receptor; CTL: cytotoxic T-cells; ITP: Immune thrombocytopenic purpura; MM: multiple myeloma; RCC: Renal cell carcinoma; RF: rheumatoid factor; ANA: antinuclear antibodies. Figures were generated with (accessed on 20 August 2021).

Clinically, LGLL patients may remain asymptomatic for many years due to the aforementioned indolent course of the disease [1][8]. However, severe neutropenia, moderate symptomatic neutropenia, transfusion-dependent anemia, or autoimmune hemolytic anemia may necessitate therapy.

2. Overview of the Main Pathways Involved in the Pathogenesis of LGLL with Possible Therapeutic Implications

The pathogenesis of LGLL suggests potential new therapeutic approaches, many of which can be adopted from the therapeutic armamentarium designed for autoimmune diseases. Indeed, multiple pathways also involved in immune responses are found to be dysregulated in LGLL. Two major categories can be identified: (i) pathways promoting survival and (ii) pathways contributing to cell ability to escape apoptosis [2][9].

The Nuclear Factor kappa β (NF-κβ) signaling pathway is another transcription factor that has been implicated in the constitutive activation of LGLL cells. Once NF-κβ protein is translocated to the nucleus, it activates several proto-oncogenes such as cyclin D1 , c-myc , and the anti-apoptotic genes BCL-2 and MCL-1 , promoting the production of IL-2 [10][11] and allowing LGLL cells to escape the physiological mechanism of activation-induced cell death (AICD) [10][12] ( Figure 1 ).

Platelet-Derived Growth Factor (PDGF) receptor heterodimeric complexes (aa, bb, and ab) can be found on CTLs. An increased expression of both PDGF receptor type b and PDGF-bb results in an autocrine loop and activation of several pathways involved in LGLL (e.g., JAK-STAT, Ras-RAF-MEK1-ERK, and PI3K-Akt) [10][13]. Consistent with these findings, antibodies targeting PDGF-bb were shown to be cytotoxic to LGLL cells [14]. Whether activated by PDGF pathways or other mechanisms (see also below), RAS-RAF-MEK1-ERK signaling is hyperactive in LGLL (particularly in the NK subtype), and its inhibition showed encouraging results in this setting via restoration of Fas sensitivity [10][15]. It is worth mentioning that a significant shift towards pro-survival sphingolipids such as sphingosine-1-phosphate (S1P) has been identified in LGLL along with downregulation of the corresponding proapoptotic ceramide and sphingosine [16]. In particular, the upregulation of rate-limiting enzymes in LGLL such as sphingosine kinase 1 (SphK1), converting sphingosine to S1P, and the upregulation of N-acylsphingosine amidohydrolase 1 (ASAH1), converting ceramide to sphingosine, may represent one of the mechanisms responsible for enhanced LGLL cell survival [10].

IL-15 is a member of the IL-2 family that controls the activation and proliferation of T- and NK-cells. This cytokine is produced by antigen-presenting cells (APCs) and exerts its effects through interaction with the soluble or membrane receptor IL-15Rα. This receptor presents IL-15 to IL-2/IL-15Rβ subunits, which are expressed in both T- and NK-LGL cells. In particular, IL-15 forms a complex with IL-2Rβ, finally resulting in activation of JAK-STAT and Ras/MAPK pathways, in addition to an unbalanced generation of antiapoptotic (Bcl-2 and Bcl-xL) and pro-apoptotic signals (Bim and Puma) [17]. Furthermore, it has been shown that LGLL cells overexpress CD122 (a receptor subunit shared by IL-2 and IL-15). Increased soluble IL-15Rα concentration has been found in patients’ sera, pointing towards an essential role of the IL-15 signaling pathway in LGLL pathogenesis and, possibly, treatment [13][17][18][19].

3. Current Therapy Approaches and Their Results

Due to the lack of randomized prospective trials, current standard treatment options in LGLL mostly rely on the metanalysis of phase II trials and case series. The mainstay of first-line therapies involves immunosuppression administered in a chronic and protracted fashion, rather than in pulse/cycle mode as is typical in many B cell lymphomas. This route of administration (chronic vs. pulses) is preferred because the proliferative fraction of memory cells for LGLL clone is low. The greatest amount of experience has been reported with methotrexate (MTX, 10 mg/m 2/weekly) , cyclosporine A (CsA, 3–5 mg/kg/day), or low dose cyclophosphamide (Cy, 50 to 100 mg/day), with or without short prednisone taper ( Table 1 ). Treating patients for at least 4–6 months is recommended before assessing response [1][2].

Table 1. Response to different therapies reported in the largest study cohorts of LGLL patients. The data presented are derived from a meta-analysis of the existing literature.

Treatments Dong et al. 2021 [8] Zhu et al. 2020 [5] Bareau et al. 2010 [20] Loughran et al. 2015 [21] Sanikommu et al. 2018 [22]
n 319 108 229 59 204
Treated (%) 181 (57%) 105 (97%) 100 (44%) 55 (93%) 1st line (MTX)
14 (23%) 2nd line (Cy)
118 (58%)
MTX (n) 89 5 62 55 61
ORR 58 (56%) 0 34 (55%) 21 (38%) 26 (43%)
CR 14 (16%) 0 13 (21%) 3 (5%)  
Cy (n) 65 9 32 14 53
ORR 40 (62%) 7 (78%) 21 (66%) 9 (64%) 28 (53%)
CR 21 (32%) 5 (56%) 15 (47%) 3 (21%)  
CsA (n) 39 99 * 24 - 74
ORR 29 (74%) 49 (49%) 5 (21%) 36 (48%)
CR 9 (23%) 20 (20%) 1 (4%)  
Alemtuzumab (n) 6 - - - 24
ORR 3 (50%) 11 (46%)
CR 1 (17%)  

* 83 of 99 patients received CsA plus steroids.

In addition to its effects on DNA replication, MTX suppresses the activation of JAK/STAT signaling [23]. Indeed, STAT3 Y640F mutant cases appear to be more likely to respond to MTX treatment [21], which is also the preferred choice when treating LGLL patients with associated rheumatoid arthritis (RA), neutropenia, or other autoimmune conditions [8]. CsA, as a calcineurin inhibitor, blocks NF-AT, IL-2, and IFN-γ expression [12]. Interestingly, the HLA-DR4 allele has been found to be overrepresented in LGLL patients with co-occurring RA. Moreover, it has been shown that HLA-DR4 carriers may have a higher likelihood of CSA responsiveness, suggesting the presence of underlying antigen-driven mechanisms in different contexts characterized by specific immunogenetic predisposition [24]. Cy appears to be a good option, especially for cases with concurrent PRCA or profound anemia [8]. Chronic daily oral administration seems to be the preferred approach rather than periodic intravenous (IV) boluses. However, it is worth noting that a lack of response to either MTX, CsA, or Cy is not uncommon, and a switch between the three should be considered in such cases [2]. In addition, Cy should not be used for more than 12 months to avoid long-term complications, as demonstrated by studies involving large cohorts of patients with rheumatologic conditions [2]. Refractory cases are not uncommon and usually present with persistent transfusion-dependent anemia or severe neutropenia, requiring >1 line of treatment in up to 30% of cases [20][22]. Response to therapy ( Table 1 ) varies between cohorts, and patients often require trials, switching among different treatments.

4. Potentially Available New Therapeutic Options and Clinical Evidence

The pathogenic overlap between autoimmune T-cell-mediated reactions and the reactive-to-semiautonomous nature of LGLL implies that many shared targets may exist in these conditions. Thus, refractory LGLL cases may be analyzed for the presence of clinical clues for rationally applied salvage therapies.

One hypothesis behind the persistent activation and proliferation of LGLL cells is the chronic exposure to “un-cleared” antigens [2]. For this purpose, medications inhibiting the cycle of T-cell activation, particularly in patients with associated autoimmune processes, provide a valid avenue for targeted treatment. Abatacept is a hybrid protein consisting of the extracellular domain of CTLA-4 linked to the Fc region of human IgG1 (CTLA4-Ig). Upon binding to CD80/CD86 on APC, abatacept blocks CD28 co-stimulation of naïve T-cells, attenuating their activation. Effective in RA [25] , we previously reported the successful treatment of patients with refractory LGLL in association with RA and neutropenia with a response seen in 4/8 patients [22][26].

IL-6 is a key cytokine activator of the JAK/STAT pathway [27]. In a homeostatic state, IL-6 binds to its membrane-bound receptor IL-6R or the soluble form sIL-6R, forming a complex with the corresponding transducer protein (gp130) [28]. This complex activates the JAK-STAT3 pathway and triggers the expression of the suppressor of the cytokine-signaling 3 ( SOCS3 ) gene responsible for this physiologic negative-feedback found to be disrupted in LGLL [27][29]. Therefore, targeting IL-6 may represent a valid approach in refractory LGLL. Tocilizumab (anti-IL6 receptor) and Siltuximab (anti-IL6) are two approved drugs for the treatment of various autoimmune conditions (e.g., RA and Castleman disease) [28][30]. Considering the association of LGLL and RA [31], IL-6 antagonists may represent another therapeutic alternative, especially for LGLL patients with RA-like features. The associated risk of transient neutropenia with tocilizumab [31] warrants caution and suggests preferential use in refractory LGLL patients with transfusion-dependent anemia.

Bortezomib is a proteasome inhibitor that downregulates the NF-kβ pathway activity, ultimately blocking the degradation of different pro-apoptotic factors [32][33]. Given its efficacy in patients with multiple myeloma, this drug may be exploited in LGLL cases refractory to T-cell-directed immunosuppression, especially when associated with monoclonal gammopathies ( Table 1 ). The successful treatment with Bortezomib of patients with PRCA/LGLL with associated MGUS was reported [34][35].


  1. Cheon, H.J.; Dziewulska, K.H.; Moosic, K.B.; Olson, K.C.; Gru, A.A.; Feith, D.J.; Loughran, T.P. Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. Curr. Hematol. Malig. Rep. 2020, 15, 103–112.
  2. Lamy, T.; Moignet, A.; Loughran, T.P. LGL leukemia: From pathogenesis to treatment. Blood Am. Soc. Hematol. 2017, 129, 1082–1094.
  3. Moignet, A.; Lamy, T. Latest Advances in the Diagnosis and Treatment of Large Granular Lymphocytic Leukemia. Am. Soc. Clin. Oncol. Educ. B 2018, 38, 616–625.
  4. Scquizzato, E.; Teramo, A.; Miorin, M.; Facco, M.; Piazza, F.; Noventa, F.; Trentin, L.; Agostini, C.; Zambello, R.; Semenzato, G.C. Genotypic evaluation of killer immunoglobulin-like receptors in NK-type lymphoproliferative disease of granular lymphocytes. Leukemia 2007, 21, 1060–1069.
  5. Zhu, Y.; Gao, Q.; Hu, J.; Liu, X.; Guan, D.; Zhang, F. Clinical features and treatment outcomes in patients with T-cell large granular lymphocytic leukemia: A single-institution experience. Leuk. Res. 2020, 90, 106299.
  6. Mohan, S.R.; Maciejewski, J.P. Diagnosis and therapy of neutropenia in large granular lymphocyte leukemia. Curr. Opin. Hematol. 2009, 16, 27–34.
  7. Sokol, L.; Loughran, T.P. Large Granular Lymphocyte Leukemia. Oncologist 2006, 11, 263–273.
  8. Dong, N.; Castillo Tokumori, F.; Isenalumhe, L.; Zhang, Y.; Tandon, A.; Knepper, T.C.; Mo, Q.; Shao, H.; Zhang, L.; Sokol, L. Large Granular Lymphocytic Leukemia—A Retrospective Study of 319 Cases. Am. J. Hematol. 2021, 96, 772–780.
  9. Steinway, S.N.; LeBlanc, F.; Loughran, T.P. The pathogenesis and treatment of large granular lymphocyte leukemia. Blood Rev. 2014, 28, 87–94.
  10. Leblanc, F.; Zhang, D.; Liu, X.; Loughran, T.P. Large granular lymphocyte leukemia: From dysregulated pathways to therapeutic targets. Future Oncol. 2012, 8, 787–801.
  11. Meng, F.; D’Mello, S.R. NF-κB stimulates Akt phosphorylation and gene expression by distinct signaling mechanisms. Biochim. Biophys. Acta—Gene Struct. Expr. 2003, 1630, 35–40.
  12. Zhang, J.; Xu, X.; Liu, Y. Activation-Induced Cell Death in T Cells and Autoimmunity. Cell. Mol. Immunol. 2004, 1, 186–192.
  13. Zhang, R.; Shah, M.V.; Yang, J.; Nyland, S.B.; Liu, X.; Yun, J.K.; Albert, R.; Loughran, T.P. Network model of survival signaling in large granular lymphocyte leukemia. Proc. Natl. Acad. Sci. USA 2008, 105, 16308–16313.
  14. Yang, J.; Liu, X.; Nyland, S.B.; Zhang, R.; Ryland, L.K.; Broeg, K.; Baab, K.T.; Jarbadan, N.R.; Irby, R.; Loughran, T.P. Platelet-derived growth factor mediates survival of leukemic large granular lymphocytes via an autocrine regulatory pathway. Blood 2010, 115, 51–60.
  15. Epling-Burnette, P.K.; Bai, F.; Wei, S.; Chaurasia, P.; Painter, J.S.; Olashaw, N.; Hamilton, A.; Sebti, S.; Djeu, J.Y.; Loughran, T.P.; et al. ERK couples chronic survival of NK cells to constitutively activated Ras in lymphoproliferative disease of granular lymphocytes (LDGL). Oncogene 2004, 23, 9220–9229.
  16. Shah, M.V.; Zhang, R.; Irby, R.; Kothapalli, R.; Liu, X.; Arrington, T.; Frank, B.; Lee, N.H.; Loughran, J.T.P. Molecular profiling of LGL leukemia reveals role of sphingolipid signaling in survival of cytotoxic lymphocytes. Blood 2008, 112, 770–781.
  17. Mishra, A.; Sullivan, L.; Caligiuri, M.A. Molecular pathways: Interleukin-15 signaling in health and in cancer. Clin. Cancer Res. 2014, 20, 2044–2050.
  18. Chen, J.; Petrus, M.; Bamford, R.; Shih, J.H.; Morris, J.C.; Janik, J.E.; Waldmann, T.A. Increased serum soluble IL-15Rα levels in T-cell large granular lymphocyte leukemia. Blood 2012, 119, 137–143.
  19. Steinway, S.N.; Loughran, T.P. Targeting IL-15 in large granular lymphocyte leukemia. Expert Rev. Clin. Immunol. 2013, 9, 405.
  20. Bareau, B.; Rey, J.; Hamidou, M.; Donadieu, J.; Morcet, J.; Reman, O.; Schleinitz, N.; Tournilhac, O.; Roussel, M.; Fest, T.; et al. Analysis of a French cohort of patients with large granular lymphocyte leukemia: A report on 229 cases. Haematologica 2010, 95, 1534–1541.
  21. Loughran, T.P.; Zickl, L.; Olson, T.; Wang, V.; Zhang, D.; Rajala, H.L.; Hasanali, Z.; Bennett, J.M.; Lazarus, H.M.; Litzow, M.R.; et al. Immunosuppressive therapy of LGL leukemia: Prospective multicenter phase II study by the Eastern Cooperative Oncology Group (E5998). Leukemia 2015, 29, 886–894.
  22. Sanikommu, S.R.; Clemente, M.J.; Chomczynski, P.; Ii, M.G.A.; Jerez, A.; Thota, S.; Patel, B.; Hirsch, C.; Nazha, A.; Desamito, J.; et al. Clinical features and treatment outcomes in large granular lymphocytic leukemia (LGLL). Leuk. Lymphoma 2018, 59, 416–422.
  23. Thomas, S.; Fisher, K.H.; Snowden, J.A.; Danson, S.J.; Brown, S.; Zeidler, M.P. Methotrexate is a JAK/STAT pathway inhibitor. PLoS ONE 2015, 10, e0130078.
  24. Battiwalla, M.; Melenhorst, J.; Saunthararajah, Y.; Nakamura, R.; Molldrem, J.; Young, N.S.; Barrett, A.J. HLA-DR4 predicts haematological response to cyclosporine in T-large granular lymphocyte lymphoproliferative disorders. Br. J. Haematol. 2003, 123, 449–453.
  25. Korhonen, R.; Moilanen, E. Abatacept, a Novel CD80/86-CD28 T Cell Co-stimulation Modulator, in the Treatment of Rheumatoid Arthritis. Basic Clin. Pharmacol. Toxicol. 2009, 104, 276–284.
  26. Bilori, B.; Thota, S.; Clemente, M.J.; Patel, B.; Jerez, A.; Ii, M.A.; Maciejewski, J.P. Tofacitinib as a novel salvage therapy for refractory T-cell large granular lymphocytic leukemia. Leukemia 2015, 29, 2427–2429.
  27. Teramo, A.; Gattazzo, C.; Passeri, F.; Lico, A.; Tasca, G.; Cabrelle, A.; Martini, V.; Frezzato, F.; Trimarco, V.; Ave, E.; et al. Intrinsic and extrinsic mechanisms contribute to maintain the JAK/STAT pathway aberrantly activated in T-type large granular lymphocyte leukemia. Blood 2013, 121, 3843–3854.
  28. Rossi, J.F.; Lu, Z.Y.; Jourdan, M.; Klein, B. Interleukin-6 as a therapeutic target. Clin. Cancer Res. 2015, 21, 1248–1257.
  29. Schmitz, J.; Weissenbach, M.; Haan, S.; Heinrich, P.C.; Schaper, F. SOCS3 exerts its inhibitory function on interleukin-6 signal transduction through the SHP2 recruitment site of gp130. J. Biol. Chem. 2000, 275, 12848–12856.
  30. Bockorny, B.; Dasanu, C.A. Autoimmune manifestations in large granular lymphocyte leukemia. Clin. Lymphoma Myeloma Leuk. 2012, 12, 400–405.
  31. Campbell, L.; Chen, C.; Bhagat, S.S.; Parker, R.A.; Ostor, A.J.K. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: A systematic literature review and meta-analysis of randomized controlled trials. Rheumatology 2011, 50, 552–562.
  32. Hideshima, T.; Richardson, P.G.; Anderson, K.C. Mechanism of action of proteasome inhibitors and deacetylase inhibitors and the biological basis of synergy in multiple myeloma. Mol. Cancer Ther. 2011, 10, 2034–2042.
  33. Hideshima, T.; Ikeda, H.; Chauhan, D.; Okawa, Y.; Raje, N.; Podar, K.; Mitsiades, C.; Munshi, N.C.; Richardson, P.G.; Carrasco, R.D.; et al. Bortezomib induces canonical nuclear factor-κB activation in multiple myeloma cells. Blood 2009, 114, 1046–1052.
  34. Balasubramanian, S.K.; Sadaps, M.; Thota, S.; Aly, M.; Przychodzen, B.P.; Hirsch, C.M.; Visconte, V.; Radivoyevitch, T.; Maciejewski, J.P. Rational management approach to pure red cell aplasia. Haematologica 2018, 103, 221–230.
  35. Gurnari, C.; Pagliuca, S.; Awada, H.; Zawit, M.; Patel, B.J.; Visconte, V.; Valent, J.; Rogers, H.J.; Maciejewski, J.P. Monoclonal IgM gammopathy in adult acquired pure red cell aplasia: Culprit or innocent bystander? Blood Cells Mol. Dis. 2021, 91, 102595.
Subjects: Hematology
Contributor MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to :
View Times: 447
Revisions: 2 times (View History)
Update Date: 26 Sep 2021